About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Phoenix | 14,291 Studies Near You | Clareo Health

Clinical Trials LocationsPhoenix

Clinical Trials in Phoenix

Discover 14,291 clinical trials near Phoenix, Arizona. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 2261-2280 of 14,291 trials

RECRUITING< 1 mile

Pancreatic Cancer Detection Consortium

NCT06388967

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

Pancreatic CancerPancreatic CarcinomaPancreatic Adenocarcinoma+10 more

City of Hope Medical Center2,000 participantsStarted Mar 2023

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Monrovia, California, United States +8 more locations

RECRUITING< 1 mile

Blue Light Cystoscopy With Cysview® Registry

NCT02660645

Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.

Photocure4,400 participantsStarted Apr 2014

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +20 more locations

Find Trials by Condition in Phoenix

Breast Cancerin Phoenix Lung Cancerin Phoenix Prostate Cancerin Phoenix Colorectal Cancerin Phoenix Melanomain Phoenix Leukemiain Phoenix Lymphomain Phoenix Pancreatic Cancerin Phoenix Ovarian Cancerin Phoenix Brain Cancerin Phoenix Diabetes

Data from ClinicalTrials.govTerms

TERMINATEDPhase 211 miles

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

NCT06077773

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Escient Pharmaceuticals, Inc113 participantsStarted Sep 2023

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Little Rock, Arkansas, United States +45 more locations

Active Not RecruitingPhase 311 miles

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

NCT06634420

This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.

Hereditary Angioedema

Intellia Therapeutics60 participantsStarted Jan 2025

Scottsdale, Arizona, United States • San Diego, California, United States • Santa Monica, California, United States +26 more locations

COMPLETEDPhase 3278 miles

A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age

NCT04464707

The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of CM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of CM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical outcomes in participants exposed to Fremanezumab The total duration of the study is planned to be 75 months.

Teva Branded Pharmaceutical Products R&D, Inc.292 participantsStarted Sep 2020

Little Rock, Arkansas, United States • Banning, California, United States • Loma Linda, California, United States +86 more locations

Active Not RecruitingPhase 4290 miles

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

NCT06571383

The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.

Novo Nordisk A/S500 participantsStarted Sep 2024

Escondido, California, United States • Orlando, Florida, United States • Tallahassee, Florida, United States +90 more locations

COMPLETEDPhase 1295 miles

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

NCT05287399

This is a Phase 1, open-label, multicenter, single-arm, dose escalation study, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of single-agent ASC61(an orally bioavailable small-molecule inhibitor of PD-L1) in subjects with advanced solid tumors for whom no standard therapy is available.

Advanced Solid Tumors

Ascletis Pharmaceuticals Co., Ltd.18 participantsStarted Aug 2022

Encinitas, California, United States • Fresno, California, United States • San Marcos, California, United States +1 more locations

Active Not RecruitingPhase 1/2296 miles

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.

Solid TumorNon-Small Cell Lung CancerHead and Neck Cancer+4 more

Inhibrx Biosciences, Inc296 participantsStarted Dec 2019

Duarte, California, United States • Glendale, California, United States • Los Angeles, California, United States +39 more locations

RECRUITINGPhase 3304 miles

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

NCT07010471

A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension

Developmental and Epileptic Encephalopathy 1

Praxis Precision Medicines160 participantsStarted Jul 2025

La Jolla, California, United States • Gulf Breeze, Florida, United States • Chevy Chase, Maryland, United States +2 more locations

COMPLETEDPhase 3333 miles

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

NCT04447118

This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemotherapy.

Non-squamous NSCLCHER2 Exon 20 Mutation

Jiangsu HengRui Medicine Co., Ltd.151 participantsStarted Sep 2020

Orange, California, United States • Sacramento, California, United States • Whittier, California, United States +99 more locations

Enrolling By Invitation333 miles

The Johns Hopkins Heartburn Center Registry

NCT03853772

A multi-center, multi-year registry of patients with gastroesophageal reflux disease (GERD) undergoing diagnostic evaluation and/or treatment of GERD and associated diseases and complications.

Gastroesophageal Reflux DiseaseBarrett EsophagusLaryngopharyngeal Reflux+1 more

Johns Hopkins University2,000 participantsStarted Apr 2019

Orange, California, United States • Baltimore, Maryland, United States • Rochester, Minnesota, United States +6 more locations

Active Not Recruiting357 miles

Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)

NCT06282432

This Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the ITGB2 gene

Leukocyte Adhesion Deficiency

Rocket Pharmaceuticals Inc.9 participantsStarted Mar 2022

Los Angeles, California, United States • Madrid, Spain • London, United Kingdom

RECRUITINGPhase 1501 miles

A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)

NCT06551142

The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.

GlaxoSmithKline590 participantsStarted Sep 2024

Stanford, California, United States • Denver, Colorado, United States • New Haven, Connecticut, United States +50 more locations

COMPLETEDPhase 3505 miles

A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement

NCT05603832

This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14 (625 mg sustained release celecoxib) administered concurrent with multimodal analgesia in patients undergoing total knee replacement surgery, compared to multimodal analgesia alone.

Post Operative Pain

Arthritis Innovation Corporation151 participantsStarted Nov 2022

Little Rock, Arkansas, United States • Tamarac, Florida, United States • Tulsa, Oklahoma, United States +4 more locations

Active Not RecruitingPhase 2505 miles

Study of Aspirin in Patients With Vestibular Schwannoma

NCT03079999

This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.

Vestibular SchwannomaAcoustic NeuromaNeurofibromatosis 2

Massachusetts Eye and Ear Infirmary97 participantsStarted Jun 2018

Stanford, California, United States • Miami, Florida, United States • Boston, Massachusetts, United States +2 more locations

Enrolling By InvitationPhase 2/3653 miles

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

NCT05883748

This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.

Erythropoietic Protoporphyria

Disc Medicine, Inc230 participantsStarted Aug 2023

Birmingham, Alabama, United States • San Francisco, California, United States • Miami, Florida, United States +10 more locations

Active Not RecruitingPhase 3840 miles

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

NCT05171075

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Venous ThromboembolismDeep Venous ThrombosisPulmonary Embolism

Anthos Therapeutics, Inc.417 participantsStarted Sep 2022

Washington D.C., District of Columbia, United States • Evanston, Illinois, United States • St Louis, Missouri, United States +114 more locations

RECRUITINGPhase 1884 miles

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

NCT04659616

This phase I trial identifies the best dose and clinical benefit of giving pemigatinib following standard induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Pemigatinib selectively inhibits FGFR (fibroblast growth factor receptor) activity, a receptor that may contribute to the growth of leukemia cells. The genetic changes responsible for activating the growth of leukemia cells can be unique to each patient and can change during the course of the disease. Chemotherapy drugs, such as cytarabine and daunorubicin work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Acute Myeloid Leukemia

OHSU Knight Cancer Institute32 participantsStarted Jan 2021

Portland, Oregon, United States • Dallas, Texas, United States

COMPLETEDPhase 11015 miles

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

NCT03573310

The purpose of the study is to identify the maximum tolerated dose (MTD) of JNJ-64619178 in participants with relapsed/refractory B cell non-Hodgkin lymphoma (NHL) or advanced solid tumors and also to identify the recommended Phase 2 dose(s) (RP2Ds) of JNJ-64619178 for NHL and advanced solid tumors (Part 1) and to confirm the tolerability of JNJ-64619178 in participants with lower risk myelodysplastic syndromes (MDS) (Part 2).

NeoplasmsSolid Tumor, AdultNon-Hodgkin Lymphoma+1 more

Janssen Research & Development, LLC114 participantsStarted Jul 2018

Sarasota, Florida, United States • Boston, Massachusetts, United States • Columbus, Ohio, United States +15 more locations

RECRUITINGNA1090 miles

CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms

NCT05663034

This study is a prospective two-arm, single blind randomized controlled trial design to compare the clinical effectiveness of telemedicine-delivered, 6-session, standardized cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based treatment for insomnia (MBTI) in treating insomnia symptoms and ameliorating depressive symptoms in persons with mild to moderate TBI and comorbid Post-Traumatic Stress Symptoms (PTSS) and insomnia symptoms in a 360 patients. Participants will undergo assessment (psychosocial questionnaires, neurocognitive testing, sleep monitoring) at baseline, at the end of treatment, and at 2-, 6- and 12-weeks post-treatment. The primary outcome is sleep as measured by the Insomnia Severity Index (ISI).

Traumatic Brain InjuryInsomniaDepression+7 more

Johns Hopkins University360 participantsStarted May 2024

Eglin Air Force Base, Florida, United States • Eglin Air Force Base, Florida, United States • Bethesda, Maryland, United States +2 more locations

PreviousPage 114 of 715Next

in Phoenix

Heart Diseasein Phoenix